Ieri, presso la Camera dei Deputati, durante la II edizione degli Stati Generali della Radioterapia Oncologica promossa da #AIRO, il confronto si è concentrato su formazione, innovazione e futuro!
Come #AIROGiovani, abbiamo partecipato attivamente! #RadOncs4Life
Here the official position of AIRO, Italian Association of Radiotherapy and Clinical Oncology in regard to IRRADIaTE, the Italian Registry of RT-Associated Urological Treatment. @EurUrolOncol . In press. https://t.co/FC1k6QmeCV thanks to @GiuliaMarvaso84 & @CiroFranzese1
Congratulations to @PierluigiBonomo on being elected President-Elect of the Italian Society of Radiation Oncology #AIRO
His attitude, energy and dedication to #radonc will be vital to shape the future of our beloved specialty! Best wishes for the journey ahead!
Airo Giovani meeting touching on the challenges and advances of radiation therapy for pediatric and AYAs patients - kudos to all the speakers @airo_young#AIRO2025
Congratulations to @emmadippolito for the outstanding presentation of the CRASCH trial at #AIRO2025! A remarkable contribution that highlights the strength and innovation of our research community. Well done, Emma! 👏🌟 #RadOnc#AIRO2025
If you’re a fan of radiation oncology and struggling to figure out why more people don’t celebrate the cancer treatments we deliver, then this editorial might be for you. @IJROBP@sueyom@NehaVapiwala
https://t.co/sa8vmX1aKx
🚀 Un’altra grande #opportunità per i nostri soci!
#AIRO bandisce 5 borse di studio per la partecipazione a corsi residenziali #ESTRO@ESTRO_RT
📌 Scadenza per la presentazione delle domande: 16 ottobre 2025.
📎 Il bando completo è disponibile in allegato.
Key findings include:
1. Excellent safety and tolerability in an elderly, unfit population.
2. Median overall survival nearly doubled compared to existing radiotherapy.
3. Promising results from combining radiotherapy with palliative doses and immunotherapy.
How do patients with HPV-positive oropharyngeal cancer experience their disease and relate to their treatment decision-making? Happy to share an insight on this still overlooked topic @ctRO_journal
https://t.co/PBN931ISLU
@ASCOPost@jingxuan_zhao@CostAnEffect These data should inform opinions on the importance of supporting universal health services, their sustainability (collaboration with pharmaceutical companies is necessary!), and equal access to care.
Study by @jingxuan_zhao, @CostAnEffect, et al, shows 2-year survival gaps widened between uninsured and privately insured patients with stage IV #Melanoma, #NSCLC, and #RCC after ICI introduction.
🔗https://t.co/nkCcq3NXhm
👏 Proud to see ESTRO President-Elect Prof Barbara Jereczek-Fossa represent #radiotherapy at @CancerPatientsE “Access for All” event in Brussels 🇪🇺
She spotlighted radiotherapy’s role in equitable cancer care across Europe. At ESTRO, we’re committed to that vision! ✨
"Radiation Oncologists - evidently not content with spending the first two decades of the 21st century running trial after trial attempting to reduce or omit their own modality from modern cancer therapy - have now shifted their efforts to an entirely new level..."
🆕This paper aims to provide a comprehensive approach to target volume definition in cutaneous and non-cutaneous squamous cell carcinoma patients👇
Perineural invasion and parotid involvement in auricular cutaneous SCC➡️Which volumes to treat in postoperative #radiotherapy❓
https://t.co/OUJzfluqeo
🧠 New review sheds light on how to select and delineate post-op radiotherapy target volumes in oral cavity SCC. A must-read for H&N specialists
🔗https://t.co/XrLxhjkQJM
#RadOnc#HeadandNeckCancer#OralCancer#Radiotherapy
🗓️ Febbraio è il mese dedicato alle 𝗠𝗮𝗹𝗮𝘁𝘁𝗶𝗲 𝗥𝗮𝗿e. Tra queste, i 𝗧𝘂𝗺𝗼𝗿𝗶 𝗥𝗮𝗿𝗶 rappresentano una sfida significativa: progetto 𝗥𝗔𝗥𝗘𝗖𝗔𝗥𝗘𝗻𝗲𝘁 (https://t.co/H0HHSJKM1m)
#RareButNotAlone#TumoriRari#RadioterapiaOncologica